Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2022-11-08 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Code of conduct under SEBI (PIT) Regulations
Regulatory Filings Classification · 95% confidence The document is titled 'Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information' and is issued pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. It details the company's internal code and procedures for handling unpublished price sensitive information (UPSI) to comply with insider trading regulations. The content is a policy document related to regulatory compliance and internal governance rather than a financial report, earnings release, or announcement of voting results. It is not a report publication announcement since it contains substantive policy content and is not merely notifying about a report release. It is also not a certification or attestation letter. The document fits best under Regulatory Filings (RNS) as it is a regulatory compliance filing that does not fit into other specific categories like governance information or remuneration information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-08 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the completion of a US FDA Good Manufacturing Practices (GMP) inspection with zero observations. It is a regulatory compliance update under SEBI Listing Obligations and Disclosure Requirements, Regulation 30. The document does not contain financial data, audit results, or detailed reports but is an announcement of an event related to regulatory compliance. The length is only 1317 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-05 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The content is an announcement of upcoming investor meetings, not a financial report, earnings release, or detailed presentation. The document length is only 1671 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-11-04 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short notice providing contact details of Key Managerial Personnel (KMP) as required under Regulation 30(5) of the SEBI Listing Regulations. It is an announcement related to corporate governance and disclosure obligations, not a financial report or detailed management information. The document length is only 1519 characters, indicating it is a brief regulatory announcement rather than a full report. It does not contain financial data, audit information, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-02 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 90% confidence The document is an announcement dated 2nd November 2022 from Piramal Pharma Limited regarding a scheduled conference call with investors and analysts to discuss the Q2 and H1 FY2023 financial results. It includes dial-in details and registration information for the call. There are no actual financial statements or detailed financial analysis included in the text. The document serves to inform about the upcoming earnings conference call rather than presenting the earnings results themselves or a transcript of the call. Therefore, it is best classified as a Call Transcript (CT) announcement or related to the earnings call event. However, since it is only an intimation of the conference call and not the transcript itself, the closest fitting category is Call Transcript (CT) as it relates directly to the earnings call event. Confidence is high given the clear context and content.
2022-11-02 English
Board Meeting — Other business matters
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 1st November 2022 from Piramal Pharma Limited addressed to stock exchanges. It informs about a forthcoming Board meeting on 8th November 2022 to consider and approve unaudited financial results for the quarter and half year ended 30th September 2022. It also mentions the closure of the trading window for securities dealing. The document does not contain any actual financial data or detailed financial statements; it is merely an announcement of an upcoming event and report approval. The length is only 1731 characters, which is quite short and consistent with an announcement rather than a full report. According to the rules, such announcements about upcoming report approvals or meetings are classified as Regulatory Filings (RNS) rather than Interim Reports (IR) or Earnings Releases (ER).
2022-11-02 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.